Osteonecrosis of the jaw related to bevacizumab

Journal of Clinical Oncology

Volumn 26, Issue 24, 2008, Pages 4037-4038

  Estilo, Cherry L ^a   Fornier, Monica ^a   Farooki, Azeez ^a   Carlson, Diane ^a   Bohle III, George ^a   Huryn, Joseph M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHLORHEXIDINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LETROZOLE; PACLITAXEL; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE NECROSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GINGIVA PAIN; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; MASTECTOMY; MORNING DOSAGE; MOUTHWASH; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; JAW DISEASE; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; JAW DISEASES; MIDDLE AGED; OSTEONECROSIS;

EID: 50549088915     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5424     Document Type: Article

References (11)

1. Van Poznak C, Estilo C: Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 20:1053-1062, 2006
2. Woo S-B, Hellstein JW, Kalmar JR: Systematic review: Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 144:753-761, 2006
3. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739, 2002
4. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380, 2002
5. Cher ML, Towler DA, Rafii S, et al: Cancer interaction with the bone microenvironment: A workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol 168:1405-1412, 2006
6. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab and capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
7. Herbst RS, O'Neill VJ, Fehrenbacher L, et al: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 25:4743-4750, 2007
8. Saif MW, Elfiky A, Salem RR: Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860-1869, 2007
9. Shih T, Lindley C: Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779-1802, 2006
10. Fakih MG, Lombardo JC: Bevacizumab-induced nasal septum perforation. The Oncologist 11:85-86, 2006
11. Traina TA, Norton L, Drucker K, et al: Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. The Oncologist 11:1070-1071, 2006